Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

610
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
610

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodality cardiovascular imaging in arrhythmic mitral valve prolapse: a state-of-the-art review from structural assessment to myocardial tissue characterization.

Frontiers in cardiovascular medicine·2026
Same author

Beyond arrhythmias: Exploring heart failure in arrhythmogenic cardiomyopathy.

International journal of cardiology·2026
Same author

Left Ventricular Hypertrabeculation: Historical Evolution, Diagnostic Pitfalls, and a Pragmatic Clinical Approach.

Reviews in cardiovascular medicine·2026
Same author

Insights Into the Natural History of Recurrent Myocarditis, A Multicenter International Study (Re-Myo Study).

Journal of the American Heart Association·2026
Same author

Clinical Characteristics and Outcomes of Patients With Biventricular and Left-Dominant Arrhythmogenic Cardiomyopathy With Ring-like Late Gadolinium Enhancement Pattern.

JACC. Clinical electrophysiology·2026
Same author

Neonatal narrow-complex SVT unmasking pre-excitation.

Journal of electrocardiology·2026

Related Experiment Video

Updated: Feb 22, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Idarucizumab: What Should We Know?

Francesca Cortese1, Giacinto Calculli2, Michele Gesualdo1

  • 1Cardiovascular disease Section, Department of Organ and Trasplantation, University of Bari, Italy.

Current Drug Targets
|September 28, 2017
PubMed
Summary
This summary is machine-generated.

Idarucizumab effectively reverses dabigatran

Keywords:
Idarucizumabanticoagulant activityanticogulant drugsantidotebleedingdabigatran

More Related Videos

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

10.5K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.9K

Related Experiment Videos

Last Updated: Feb 22, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

10.5K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.9K

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Idarucizumab is a specific antidote for dabigatran, a direct thrombin inhibitor.
  • Approved for reversing dabigatran-related bleeding and in emergency procedures.
  • Used to manage bleeding risks associated with dabigatran in high-risk surgeries.

Purpose of the Study:

  • To review idarucizumab's efficacy and safety based on existing literature.
  • To assess idarucizumab's role in clinical practice for dabigatran reversal.

Main Methods:

  • Extensive literature search in PubMed, EMBASE, and Cochrane Library.
  • Used "idarucizumab," "dabigatran," and combinations as MeSH terms.
  • Focused on high-impact investigations and available data.

Main Results:

  • Studies confirm idarucizumab reverses laboratory measures of dabigatran coagulopathy.
  • Real-world efficacy and safety data in patients remain limited.
  • Post-market surveillance is needed to clarify clinical outcomes.

Conclusions:

  • Idarucizumab is a valuable clinical tool for managing dabigatran.
  • Rapid restoration of anticoagulation simplifies dabigatran use.
  • Further real-world data is essential for comprehensive assessment.